In a large global phase 3 trial, investigators evaluated whether adding the CD19-targeted monoclonal antibody tafasitamab to the established lenalidomide–rituximab regimen could improve outcomes for adults...
Recognizing the lack of actionable monitoring guidance in transthyretin amyloid cardiomyopathy, international experts recently reviewed published prognostic data and updated proposed criteria to help...
A pooled analysis of 4 MagnetisMM trials evaluated dosing strategies for elranatamab, a BCMA-CD3 bispecific antibody, to identify the optimal regimen that mitigates cytokine release syndrome in patients...
An open-label, randomized trial found that daratumumab and hyaluronidase-fihj administered subcutaneously improved the risk of disease progression or death in patients with multiple myeloma. As a result,...
A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...
A large real-world cohort study presented at 67th ASH Annual Meeting and Exposition examined whether adding low-dose aspirin to warfarin improves outcomes in patients with antiphospholipid syndrome and...
A randomized phase III study evaluated whether a carfilzomib-based triplet regimen could improve depth of response and progression-free survival compared with standard bortezomib-based therapy in patients...
A new national analysis provides clinicians with evidence on how chronic obstructive pulmonary disease affects post-discharge outcomes in adults with sickle cell disease hospitalized for acute chest...
A large contemporary U.S. electronic health record analysis highlights elevated risks of severe maternal morbidity and preterm birth among pregnant individuals with sickle cell disease, offering updated...
A new multicenter UK audit evaluated dapagliflozin use in adults with sickle cell disease–associated chronic kidney disease, offering clinicians early insight into safety, tolerability, and renal effects in...
